USFDA issues six observations after inspection of Biocon's Malaysian arm manufacturing facility

A Biocon spokesperson said the company is confident of addressing these observations through procedural enhancements and an appropriate Corrective and Preventive Action Plan (CAPA), which will be submitted to the USFDA in the stipulated time.

from International-News-Economic Times https://ift.tt/3AIlFmD
via IFTTT

SHARE